Literature DB >> 25288327

A clinical research integration special program (CRISP) for young women with primary ovarian insufficiency.

A Falorni1, V Minarelli, C M Eads, C M Joachim, L Persani, R Rossetti, P Yurttas Beim, V A Pellegrini, P F Schnatz, S Rafique, K Kissell, K A Calis, V Popat, L M Nelson.   

Abstract

Large-scale medical sequencing provides a focal point around which to reorganize health care and health care research. Mobile health (mHealth) is also currently undergoing explosive growth and could be another innovation that will change the face of future health care. We are employing primary ovarian insufficiency (POI) as a model rare condition to explore the intersection of these potentials. As both sequencing capabilities and our ability to intepret this information improve, sequencing for medical purposes will play an increasing role in health care beyond basic research: it will help guide the delivery of care to patients. POI is a serious chronic disorder and syndrome characterized by hypergonadotrophic hypogonadism before the age of 40 years and most commonly presents with amenorrhea. It may have adverse health effects that become fully evident years after the initial diagnosis. The condition is most commonly viewed as one of infertility, however, it may also be associated with adverse long-term outcomes related to inadequate bone mineral density, increased risk of cardiovascular disease, adrenal insufficiency, hypothyroidism and, if pregnancy ensues, having a child with Fragile X Syndrome. There may also be adverse outcomes related to increased rates of anxiety and depression. POI is also a rare disease, and accordingly, presents special challenges. Too often advances in research are not effectively integrated into community care at the point of service for those with rare diseases. There is a need to connect community health providers in real time with investigators who have the requisite knowledge and expertise to help manage the rare disease and to conduct ongoing research. Here we review the pathophysiology and management of POI and propose the development of an international Clinical Research Integration Special Program (CRISP) for the condition.

Entities:  

Mesh:

Year:  2014        PMID: 25288327      PMCID: PMC4532281     

Source DB:  PubMed          Journal:  Panminerva Med        ISSN: 0031-0808            Impact factor:   5.197


  140 in total

1.  Outcomes of treatment for hepatitis C virus infection by primary care providers.

Authors:  Sanjeev Arora; Karla Thornton; Glen Murata; Paulina Deming; Summers Kalishman; Denise Dion; Brooke Parish; Thomas Burke; Wesley Pak; Jeffrey Dunkelberg; Martin Kistin; John Brown; Steven Jenkusky; Miriam Komaromy; Clifford Qualls
Journal:  N Engl J Med       Date:  2011-06-01       Impact factor: 91.245

2.  Measuring adrenal autoantibody response: interlaboratory concordance in the first international serum exchange for the determination of 21-hydroxylase autoantibodies.

Authors:  Alberto Falorni; Shu Chen; Renato Zanchetta; Liping Yu; Claudio Tiberti; Maria Luisa Bacosi; Jadwiga Furmaniak; Vittorio Bini; Francesco Dotta; George S Eisenbarth; Bernard Rees Smith; Corrado Betterle
Journal:  Clin Immunol       Date:  2011-04-28       Impact factor: 3.969

Review 3.  Clinical review 93: Autoimmune polyglandular syndrome type 1.

Authors:  C Betterle; N A Greggio; M Volpato
Journal:  J Clin Endocrinol Metab       Date:  1998-04       Impact factor: 5.958

4.  Serum gonadotropin and steroid patterns during the normal menstrual cycle.

Authors:  D R Mishell; R M Nakamura; P G Crosignani; S Stone; K Kharma; Y Nagata; I H Thorneycroft
Journal:  Am J Obstet Gynecol       Date:  1971-09       Impact factor: 8.661

5.  Immunofluorescence studies on autoantibodies to steroid-producing cells, and to germline cells in endocrine disease and infertility.

Authors:  F Sotsiou; G F Bottazzo; D Doniach
Journal:  Clin Exp Immunol       Date:  1980-01       Impact factor: 4.330

6.  Biochemical and histologic effects of sequential estrogen/progestin therapy on the endometrium of postmenopausal women.

Authors:  W E Gibbons; D L Moyer; R A Lobo; S Roy; D R Mishell
Journal:  Am J Obstet Gynecol       Date:  1986-02       Impact factor: 8.661

7.  The significance of fragile X mental retardation gene 1 CGG repeat sizes in the normal and intermediate range in women with primary ovarian insufficiency.

Authors:  M Voorhuis; N C Onland-Moret; F Janse; H K Ploos van Amstel; A J Goverde; C B Lambalk; J S E Laven; Y T van der Schouw; F J M Broekmans; B C J M Fauser
Journal:  Hum Reprod       Date:  2014-05-07       Impact factor: 6.918

8.  Myasthenia gravis and premature ovarian failure.

Authors:  Monique M Ryan; H Royden Jones
Journal:  Muscle Nerve       Date:  2004-08       Impact factor: 3.217

9.  Low levels of serum inhibin A and inhibin B in women with hypergonadotropic amenorrhea and evidence of high levels of activin A in women with hypothalamic amenorrhea.

Authors:  F Petraglia; B Hartmann; S Luisi; P Florio; S Kirchengast; M Santuz; A D Genazzani; A R Genazzani
Journal:  Fertil Steril       Date:  1998-11       Impact factor: 7.329

10.  Cost-effectiveness of a multicondition collaborative care intervention: a randomized controlled trial.

Authors:  Wayne Katon; Joan Russo; Elizabeth H B Lin; Julie Schmittdiel; Paul Ciechanowski; Evette Ludman; Do Peterson; Bessie Young; Michael Von Korff
Journal:  Arch Gen Psychiatry       Date:  2012-05
View more
  4 in total

Review 1.  Fragile X Associated Primary Ovarian Insufficiency (FXPOI): Case Report and Literature Review.

Authors:  Dorothy A Fink; Lawrence M Nelson; Reed Pyeritz; Josh Johnson; Stephanie L Sherman; Yoram Cohen; Shai E Elizur
Journal:  Front Genet       Date:  2018-11-27       Impact factor: 4.599

2.  The Improvement Effect of D-Chiro-Inositol and Ecklonia cava K. in the Rat Model of Polycystic Ovarian Syndrome.

Authors:  Hyun Yang; Sang R Lee; Seong Lae Jo; Ae-Hyang Kim; Eun-Ryoung Kim; Fan Qu; Eui-Ju Hong; Hye Won Lee
Journal:  Front Pharmacol       Date:  2022-07-19       Impact factor: 5.988

Review 3.  Premature Ovarian Insufficiency: Past, Present, and Future.

Authors:  Seung Joo Chon; Zobia Umair; Mee-Sup Yoon
Journal:  Front Cell Dev Biol       Date:  2021-05-10

4.  Welsh Onion Root (Allium fistulosum) Restores Ovarian Functions from Letrozole Induced-Polycystic Ovary Syndrome.

Authors:  Young Ho Lee; Hyun Yang; Sang R Lee; Sun Woo Kwon; Eui-Ju Hong; Hye Won Lee
Journal:  Nutrients       Date:  2018-10-04       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.